Muhammad Hassan Majeed1, Syed Ali Amir Sherazi2, Douglas Bacon3, Zahid H Bajwa4. 1. Division of Psychiatry, Natchaug Hospital, 11 A Stott Ave, Norwich, CT, 06360, USA. Hassan.Majeed@Icloud.com. 2. Division of Psychiatry, Natchaug Hospital, Norwich, CT, USA. 3. Department of Anesthesiology, The University of Mississippi Medical Center School of Medicine Jackson, Jackson, MS, 39120, USA. 4. Boston Headache Institute, and Director, Clinical Research at Boston PainCare, 85 First Ave, Waltham, MA, 02451, USA.
Abstract
PURPOSE OF REVIEW: Osteoarthritis (OA) is the most common form of arthritis that is characterized by loss of articular cartilage and new formation of bone. Pain and functional disability are common features that lead to disability and poor quality of life. This review discusses the current state of knowledge concerning the treatment of pain in OA, with a focus on pharmacological treatments. This includes the use of non-steroidal anti-inflammatory drugs, acetaminophen, and other disease-modifying agents. RECENT FINDINGS: An updated review of the role of anti-nerve growth factor monoclonal antibodies and other novel agents in the treatment of OA is also presented. In addition, a discussion of current research on biological agents such as small molecules targeting ion channels and G protein-coupled receptors is included. These new pharmacological interventions expand the frontier for treatment of patients with OA. The purpose of the review is to provide clinicians with information about the effectiveness of different pharmacological modalities in order to enable them to make the best choices for the treatment of their patients.
PURPOSE OF REVIEW: Osteoarthritis (OA) is the most common form of arthritis that is characterized by loss of articular cartilage and new formation of bone. Pain and functional disability are common features that lead to disability and poor quality of life. This review discusses the current state of knowledge concerning the treatment of pain in OA, with a focus on pharmacological treatments. This includes the use of non-steroidal anti-inflammatory drugs, acetaminophen, and other disease-modifying agents. RECENT FINDINGS: An updated review of the role of anti-nerve growth factor monoclonal antibodies and other novel agents in the treatment of OA is also presented. In addition, a discussion of current research on biological agents such as small molecules targeting ion channels and G protein-coupled receptors is included. These new pharmacological interventions expand the frontier for treatment of patients with OA. The purpose of the review is to provide clinicians with information about the effectiveness of different pharmacological modalities in order to enable them to make the best choices for the treatment of their patients.
Authors: Bruno R da Costa; Stephan Reichenbach; Noah Keller; Linda Nartey; Simon Wandel; Peter Jüni; Sven Trelle Journal: Lancet Date: 2017-07-08 Impact factor: 79.321
Authors: D T Felson; R C Lawrence; P A Dieppe; R Hirsch; C G Helmick; J M Jordan; R S Kington; N E Lane; M C Nevitt; Y Zhang; M Sowers; T McAlindon; T D Spector; A R Poole; S Z Yanovski; G Ateshian; L Sharma; J A Buckwalter; K D Brandt; J F Fries Journal: Ann Intern Med Date: 2000-10-17 Impact factor: 25.391
Authors: Wing Sum Siu; Wai Ting Shum; Wen Cheng; Chun Wai Wong; Hoi Ting Shiu; Chun Hay Ko; Ping Chung Leung; Christopher Wai Kei Lam; Chun Kwok Wong Journal: Chin Med Date: 2019-12-09 Impact factor: 5.455